{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:04:19Z","timestamp":1784063059416,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"DOI":"10.7759\/cureus.112667","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T20:43:41Z","timestamp":1784061821000},"source":"Crossref","is-referenced-by-count":0,"title":["Von Hippel-Lindau Syndrome: An Updated Narrative Review for the First-Contact Clinician"],"prefix":"10.7759","author":[{"given":"Alan Alberto","family":"P\u00e9rez-Arzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel Enrique","family":"Crisanto-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marelen","family":"Cruz-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ju\u00e1rez-Melchor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Yescas-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Arriada-Mendicoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Alberto","family":"G\u00f3mez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximiliano","family":"Orozco-Pla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Ram\u00edrez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Von Hippel-Lindau Syndrome","author":"van Leeuwaarde RS","year":"2000","unstructured":"van Leeuwaarde RS, Ahmad S, van Nesselrooij B, Zandee W, Giles RH. Von Hippel-Lindau Syndrome. GeneReviews\u00ae. Adam MP, Bick S, Mirzaa GM, et al. (ed): University of Washington, Seattle, WA; 2000."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae310","article-title":"Pancreatic neuroendocrine tumors in French VHL mutation carriers","volume":"110","author":"Muller M","year":"2025","unstructured":"Muller M, Hammel P, Couvelard A, et al.. Pancreatic neuroendocrine tumors in French VHL mutation carriers. J Clin Endocrinol Metab. 2025, 110:e1160-e1166. 10.1210\/clinem\/dgae310","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-10403-8","article-title":"Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies","volume":"52","author":"Harbi E","year":"2025","unstructured":"Harbi E, Aschner M. Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies. Mol Biol Rep. 2025, 52:281. 10.1007\/s11033-025-10403-8","journal-title":"Mol Biol Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/BF01994821","article-title":"\u00dcber eine sehr seltene Erkrankung der Netzhaut","volume":"59","author":"v Hippel E","year":"1904","unstructured":"v Hippel E. \u00dcber eine sehr seltene Erkrankung der Netzhaut. Graefes Arhiv f\u00fcr Ophthalmologie. 1904, 59:83-106. 10.1007\/BF01994821","journal-title":"Graefes Arhiv f\u00fcr Ophthalmologie"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.1926.tb07786.x","article-title":"Zur frage der angiomatosis retinae und ihrer hirnkomplikationen","volume":"4","author":"Lindau A","year":"2009","unstructured":"Lindau A. Zur frage der angiomatosis retinae und ihrer hirnkomplikationen. Acta Ophthalmol. 2009, 4:193-226. 10.1111\/j.1755-3768.1926.tb07786.x","journal-title":"Acta Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3844","article-title":"VHL, the story of a tumour suppressor gene","volume":"15","author":"Gossage L","year":"2015","unstructured":"Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015, 15:55-64. 10.1038\/nrc3844","journal-title":"Nat Rev Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf015","article-title":"\"Incidentally\" discovered Von Hippel Lindau disease: an emerging clinical phenotype","volume":"30","author":"Trinh MN","year":"2025","unstructured":"Trinh MN, Bear L, Nahed BV, Iliopoulos O. \"Incidentally\" discovered Von Hippel Lindau disease: an emerging clinical phenotype. Oncologist. 2025, 30:oyaf015. 10.1093\/oncolo\/oyaf015","journal-title":"Oncologist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03060-w","article-title":"Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States","volume":"19","author":"Jonasch E","year":"2024","unstructured":"Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M. Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States. Orphanet J Rare Dis. 2024, 19:73. 10.1186\/s13023-024-03060-w","journal-title":"Orphanet J Rare Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34896","article-title":"Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance","volume":"129","author":"Daniels AB","year":"2023","unstructured":"Daniels AB, Tirosh A, Huntoon K, et al.. Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023, 129:2927-2940. 10.1002\/cncr.34896","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.12.008","article-title":"Epidemiology and economic burden of von Hippel-Lindau disease-associated renal cell carcinoma in the United States","volume":"21","author":"Jonasch E","year":"2023","unstructured":"Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M. Epidemiology and economic burden of von Hippel-Lindau disease-associated renal cell carcinoma in the United States. Clin Genitourin Cancer. 2023, 21:238-247. 10.1016\/j.clgc.2022.12.008","journal-title":"Clin Genitourin Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad153","article-title":"Spinal cord hemangioblastomas in von Hippel-Lindau disease","volume":"6","author":"Kreatsoulas DC","year":"2024","unstructured":"Kreatsoulas DC, Lonser RR. Spinal cord hemangioblastomas in von Hippel-Lindau disease. Neurooncol Adv. 2024, 6:iii66-iii72. 10.1093\/noajnl\/vdad153","journal-title":"Neurooncol Adv"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/genes13020362","article-title":"The role of VHL in the development of von Hippel-Lindau disease and erythrocytosis","volume":"13","author":"Hudler P","year":"2022","unstructured":"Hudler P, Urbancic M. The role of VHL in the development of von Hippel-Lindau disease and erythrocytosis. Genes (Basel). 2022, 13:362. 10.3390\/genes13020362","journal-title":"Genes (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.854365","article-title":"VHL-P138R and VHL-L163R novel variants: mechanisms of VHL pathogenicity involving HIF-dependent and HIF-independent actions","volume":"13","author":"Math\u00f3 C","year":"2022","unstructured":"Math\u00f3 C, Fern\u00e1ndez MC, Bonanata J, et al.. VHL-P138R and VHL-L163R novel variants: mechanisms of VHL pathogenicity involving HIF-dependent and HIF-independent actions. Front Endocrinol (Lausanne). 2022, 13:854365. 10.3389\/fendo.2022.854365","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose TL","year":"2024","unstructured":"Rose TL, Kim WY. Renal cell carcinoma: a review. JAMA. 2024, 332:1001-1010. 10.1001\/jama.2024.12848","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01800-z","article-title":"Saturation genome editing maps the functional spectrum of pathogenic VHL alleles","volume":"56","author":"Buckley M","year":"2024","unstructured":"Buckley M, Terwagne C, Ganner A, et al.. Saturation genome editing maps the functional spectrum of pathogenic VHL alleles. Nat Genet. 2024, 56:1446-1455. 10.1038\/s41588-024-01800-z","journal-title":"Nat Genet"},{"key":"ref16","unstructured":"VHL von Hippel-Lindau tumor suppressor. (2025). Accessed. December 31, 2025: https:\/\/www.ncbi.nlm.nih.gov\/gene\/7428."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luaf055","article-title":"A corticotropin-secreting adenoma in the setting of von Hippel-Lindau disease","volume":"3","author":"Chen X","year":"2025","unstructured":"Chen X, Zhou Y, Lu L, Feng M, Wang L, Tong A. A corticotropin-secreting adenoma in the setting of von Hippel-Lindau disease. JCEM Case Rep. 2025, 3:luaf055. 10.1210\/jcemcr\/luaf055","journal-title":"JCEM Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062751","article-title":"Mosaic form of von Hippel-Lindau syndrome: case report and literature review","volume":"26","author":"Mikhaylenko DS","year":"2025","unstructured":"Mikhaylenko DS, Kuryakova NB, Efremova AV, Volodin IV, Kutsev SI, Zaletaev DV, Strelnikov VV. Mosaic form of von Hippel-Lindau syndrome: case report and literature review. Int J Mol Sci. 2025, 26:2751. 10.3390\/ijms26062751","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.v12i1.381","article-title":"Novel case of bilateral adrenal tumors confirms pathogenicity of the previously described c.463+4C>G variant in the von Hippel-Lindau gene","volume":"12","author":"Morriss S","year":"2025","unstructured":"Morriss S, Beshay V, Leong HS, Winship I. Novel case of bilateral adrenal tumors confirms pathogenicity of the previously described c.463+4C>G variant in the von Hippel-Lindau gene. J Kid Cancer. 2025, 12:23-26. 10.15586\/jkcvhl.v12i1.381","journal-title":"J Kid Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-95875-1","article-title":"Molecular dynamics reveal potential effects of novel VHL variants on VHL-Elongin C binding in ccRCC patients from Eastern India","volume":"15","author":"Chatterjee S","year":"2025","unstructured":"Chatterjee S, Paul N, Das A, et al.. Molecular dynamics reveal potential effects of novel VHL variants on VHL-Elongin C binding in ccRCC patients from Eastern India. Sci Rep. 2025, 15:13022. 10.1038\/s41598-025-95875-1","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117339","article-title":"Osteocytic oxygen sensing: distinct impacts of VHL and HIF-2alpha on bone integrity","volume":"192","author":"Mendoza SV","year":"2025","unstructured":"Mendoza SV, Wells KV, Murugesh DK, et al.. Osteocytic oxygen sensing: distinct impacts of VHL and HIF-2alpha on bone integrity. Bone. 2025, 192:117339. 10.1016\/j.bone.2024.117339","journal-title":"Bone"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1159\/000543119","article-title":"Novel von Hippel-Lindau germline variants in Iranian patients with retinal capillary hemangioblastoma","volume":"16","author":"Azimi F","year":"2025","unstructured":"Azimi F, Bagherzadeh K, Khakpoor G, et al.. Novel von Hippel-Lindau germline variants in Iranian patients with retinal capillary hemangioblastoma. Case Rep Ophthalmol. 2025, 16:74-85. 10.1159\/000543119","journal-title":"Case Rep Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-025-05694-6","article-title":"Ocular manifestations in pediatric tumor suppressor gene mutations: a case series and literature review of RB1, NF1, NF2, VHL, and TSC","volume":"25","author":"Wang A","year":"2025","unstructured":"Wang A, Wang C, Li W, Qiao J, Luo Y, Tian Y. Ocular manifestations in pediatric tumor suppressor gene mutations: a case series and literature review of RB1, NF1, NF2, VHL, and TSC. BMC Pediatr. 2025, 25:371. 10.1186\/s12887-025-05694-6","journal-title":"BMC Pediatr"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.v9i1.206","article-title":"Von Hippel-Lindau syndrome: medical syndrome or surgical syndrome? A surgical perspective","volume":"9","author":"Coco D","year":"2022","unstructured":"Coco D, Leanza S. Von Hippel-Lindau syndrome: medical syndrome or surgical syndrome? A surgical perspective. J Kidney Cancer VHL. 2022, 9:27-32. 10.15586\/jkcvhl.v9i1.206","journal-title":"J Kidney Cancer VHL"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0260","article-title":"Genotype-specific neoplastic risk profiles in patients with VHL disease","volume":"32","author":"Ganner A","year":"2025","unstructured":"Ganner A, Ferrara AM, Sekula P, et al.. Genotype-specific neoplastic risk profiles in patients with VHL disease. Endocr Relat Cancer. 2025, 32:e240260. 10.1530\/ERC-24-0260","journal-title":"Endocr Relat Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.80774","article-title":"Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata","volume":"11","author":"Ohh M","year":"2022","unstructured":"Ohh M, Taber CC, Ferens FG, Tarade D. Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata. Elife. 2022, 11:e80774. 10.7554\/eLife.80774","journal-title":"Elife"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14843","article-title":"Genotype-phenotype correlation in von Hippel-Lindau disease","volume":"99","author":"Reich M","year":"2021","unstructured":"Reich M, Jaegle S, Neumann-Haefelin E, et al.. Genotype-phenotype correlation in von Hippel-Lindau disease. Acta Ophthalmol. 2021, 99:e1492-e1500. 10.1111\/aos.14843","journal-title":"Acta Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2024.07.158","article-title":"Dual manifestations: spinal and cerebellar hemangioblastomas indicative of von Hippel-Lindau syndrome","volume":"19","author":"Setyawan NH","year":"2024","unstructured":"Setyawan NH, Hartanto RA, Malueka RG, Dwianingsih EK, Dharma DP. Dual manifestations: spinal and cerebellar hemangioblastomas indicative of von Hippel-Lindau syndrome. Radiol Case Rep. 2024, 19:5000-5006. 10.1016\/j.radcr.2024.07.158","journal-title":"Radiol Case Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1055\/a-2501-8628","article-title":"Morphology of retinal hemangioblastoma in von Hippel-Lindau disease revealed by optical coherence tomography angiography","author":"Laich Y","year":"2025","unstructured":"Laich Y, Lang SJ, Glatz A, et al.. Morphology of retinal hemangioblastoma in von Hippel-Lindau disease revealed by optical coherence tomography angiography. Klin Monbl Augenheilkd. 2025, 10.1055\/a-2501-8628","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4103\/tjo.TJO-D-24-00116","article-title":"Retinal vascular proliferation with fibrotic regression in von Hippel-Lindau disease","volume":"15","author":"Chen JY","year":"2025","unstructured":"Chen JY, Chou HD, Chao AN, Lai CC, Sagoo MS. Retinal vascular proliferation with fibrotic regression in von Hippel-Lindau disease. Taiwan J Ophthalmol. 2025, 15:138-142. 10.4103\/tjo.TJO-D-24-00116","journal-title":"Taiwan J Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2022.04.13","article-title":"Neuropathologic features of central nervous system hemangioblastoma","volume":"56","author":"Yoda RA","year":"2022","unstructured":"Yoda RA, Cimino PJ. Neuropathologic features of central nervous system hemangioblastoma. J Pathol Transl Med. 2022, 56:115-125. 10.4132\/jptm.2022.04.13","journal-title":"J Pathol Transl Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2024.08.032","article-title":"Understanding adult central nervous system hemangioblastomas: a systematic review","volume":"191","author":"Jankovic D","year":"2024","unstructured":"Jankovic D, Selimovic E, Kuharic M, Splavski B, Rotim K, Arnautovic KI. Understanding adult central nervous system hemangioblastomas: a systematic review. World Neurosurg. 2024, 191:119-127. 10.1016\/j.wneu.2024.08.032","journal-title":"World Neurosurg"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.4469","article-title":"Review of the neurological implications of von Hippel-Lindau disease","volume":"75","author":"Dornbos D 3rd","year":"2018","unstructured":"Dornbos D 3rd, Kim HJ, Butman JA, Lonser RR. Review of the neurological implications of von Hippel-Lindau disease. JAMA Neurol. 2018, 75:620-627. 10.1001\/jamaneurol.2017.4469","journal-title":"JAMA Neurol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-04213-2","article-title":"Preoperative angiographic considerations and neurological outcome after surgical treatment of intradural spinal hemangioblastoma: a multicenter retrospective case series","volume":"161","author":"Butenschoen VM","year":"2023","unstructured":"Butenschoen VM, Schwendner M, Hubertus V, et al.. Preoperative angiographic considerations and neurological outcome after surgical treatment of intradural spinal hemangioblastoma: a multicenter retrospective case series. J Neurooncol. 2023, 161:107-115. 10.1007\/s11060-022-04213-2","journal-title":"J Neurooncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3171\/CASE21296","article-title":"Multiple VHL-related hemangioblastomas and holocord syrinx: identifying the causative lesion. Illustrative case","volume":"2","author":"Mortazavi A","year":"2021","unstructured":"Mortazavi A, Nwokoye D, Asuzu DT, Scott G, Mastorakos P, Chittiboina P. Multiple VHL-related hemangioblastomas and holocord syrinx: identifying the causative lesion. Illustrative case. J Neurosurg Case Lessons. 2021, 2:CASE21296. 10.3171\/CASE21296","journal-title":"J Neurosurg Case Lessons"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1725033","article-title":"Endolymphatic sac tumor screening and diagnosis in von Hippel-Lindau disease: a consensus statement","volume":"83","author":"Mehta GU","year":"2022","unstructured":"Mehta GU, Kim HJ, Gidley PW, et al.. Endolymphatic sac tumor screening and diagnosis in von Hippel-Lindau disease: a consensus statement. J Neurol Surg B Skull Base. 2022, 83:e225-e231. 10.1055\/s-0041-1725033","journal-title":"J Neurol Surg B Skull Base"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2022.104538","article-title":"von Hippel-Lindau disease: updated guideline for diagnosis and surveillance","volume":"65","author":"Louise M Binderup M","year":"2022","unstructured":"Louise M Binderup M, Smerdel M, Borgwadt L, et al.. von Hippel-Lindau disease: updated guideline for diagnosis and surveillance. Eur J Med Genet. 2022, 65:104538. 10.1016\/j.ejmg.2022.104538","journal-title":"Eur J Med Genet"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2592","article-title":"Belzutifan for von Hippel-Lindau disease: pancreatic lesion population of the phase 2 LITESPARK-004 study","volume":"30","author":"Else T","year":"2024","unstructured":"Else T, Jonasch E, Iliopoulos O, et al.. Belzutifan for von Hippel-Lindau disease: pancreatic lesion population of the phase 2 LITESPARK-004 study. Clin Cancer Res. 2024, 30:1750-1757. 10.1158\/1078-0432.CCR-23-2592","journal-title":"Clin Cancer Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2023.04.011","article-title":"von Hippel-Lindau and hypoxia-inducible factor at the center of renal cell carcinoma biology","volume":"37","author":"Shirole NH","year":"2023","unstructured":"Shirole NH, Kaelin WG Jr. von Hippel-Lindau and hypoxia-inducible factor at the center of renal cell carcinoma biology. Hematol Oncol Clin North Am. 2023, 37:809-825. 10.1016\/j.hoc.2023.04.011","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.v11i1.275","article-title":"A narrative review of pheochromocytoma in VHL","volume":"11","author":"Coco D","year":"2024","unstructured":"Coco D, Leanza S. A narrative review of pheochromocytoma in VHL. J Kidney Cancer VHL. 2024, 11:19-23. 10.15586\/jkcvhl.v11i1.275","journal-title":"J Kidney Cancer VHL"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.84781","article-title":"Bilateral pheochromocytoma in a child revealing von Hippel-Lindau disease","volume":"17","author":"Echcharii N","year":"2025","unstructured":"Echcharii N, Chekhlabi N, Rami A, Miqdadi A, Dini N. Bilateral pheochromocytoma in a child revealing von Hippel-Lindau disease. Cureus. 2025, 17:e84781. 10.7759\/cureus.84781","journal-title":"Cureus"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3340\/jkns.2025.0018","article-title":"Von Hippel-Lindau disease: a comprehensive review of diagnosis, genetics, clinical challenges, and surveillance","volume":"68","author":"Jung NY","year":"2025","unstructured":"Jung NY, Park JB. Von Hippel-Lindau disease: a comprehensive review of diagnosis, genetics, clinical challenges, and surveillance. J Korean Neurosurg Soc. 2025, 68:338-349. 10.3340\/jkns.2025.0018","journal-title":"J Korean Neurosurg Soc"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1296555","article-title":"Case report: obstructive azoospermia as the first presentation of Von Hippel-Lindau disease","volume":"13","author":"Scafa R","year":"2023","unstructured":"Scafa R, Merico M, Ferrara AM, et al.. Case report: obstructive azoospermia as the first presentation of Von Hippel-Lindau disease. Front Oncol. 2023, 13:1296555. 10.3389\/fonc.2023.1296555","journal-title":"Front Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-025-05196-0","article-title":"Bilateral papillary cystadenoma of the broad ligament: a manifestation of Von Hippel-Lindau disease: a case report","volume":"19","author":"Bergaoui H","year":"2025","unstructured":"Bergaoui H, Ghaddab I, Dhouib W, et al.. Bilateral papillary cystadenoma of the broad ligament: a manifestation of Von Hippel-Lindau disease: a case report. J Med Case Rep. 2025, 19:159. 10.1186\/s13256-025-05196-0","journal-title":"J Med Case Rep"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/jon.12575","article-title":"Pediatric congenital cerebrovascular anomalies","volume":"29","author":"Goyal P","year":"2019","unstructured":"Goyal P, Mangla R, Gupta S, Malhotra A, Almast J, Sapire J, Kolar B. Pediatric congenital cerebrovascular anomalies. J Neuroimaging. 2019, 29:165-181. 10.1111\/jon.12575","journal-title":"J Neuroimaging"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000001246","article-title":"Immunohistochemical expression of PAX8 in central nervous system hemangioblastomas: a potential diagnostic pitfall for neuropathologists","volume":"33","author":"Broggi G","year":"2025","unstructured":"Broggi G, Farina J, Barresi V, Certo F, Barbagallo GM, Magro G, Caltabiano R. Immunohistochemical expression of PAX8 in central nervous system hemangioblastomas: a potential diagnostic pitfall for neuropathologists. Appl Immunohistochem Mol Morphol. 2025, 33:160-163. 10.1097\/PAI.0000000000001246","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34265","article-title":"Multidisciplinary integrated care pathway for von Hippel-Lindau disease","volume":"128","author":"Wolters WP","year":"2022","unstructured":"Wolters WP, Dreijerink KM, Giles RH, et al.. Multidisciplinary integrated care pathway for von Hippel-Lindau disease. Cancer. 2022, 128:2871-2879. 10.1002\/cncr.34265","journal-title":"Cancer"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/humu.21219","article-title":"Genetic analysis of von Hippel-Lindau disease","volume":"31","author":"Nordstrom-O'Brien M","year":"2010","unstructured":"Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, et al.. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010, 31:521-537. 10.1002\/humu.21219","journal-title":"Hum Mutat"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddad039","article-title":"Variant spectrum of von Hippel-Lindau disease and its genomic heterogeneity in Japan","volume":"32","author":"Tamura K","year":"2023","unstructured":"Tamura K, Kanazashi Y, Kawada C, et al.. Variant spectrum of von Hippel-Lindau disease and its genomic heterogeneity in Japan. Hum Mol Genet. 2023, 32:2046-2054. 10.1093\/hmg\/ddad039","journal-title":"Hum Mol Genet"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.24875\/BMHIM.20000129","article-title":"Familial erythrocytosis 2 and von Hippel-Lindau disease in the same pediatric patient","volume":"78","author":"N\u00fa\u00f1ez-Mart\u00ednez PM","year":"2021","unstructured":"N\u00fa\u00f1ez-Mart\u00ednez PM, Taja-Chayeb L, Ram\u00edrez-Otero MA, Fragoso-Ontiveros V, Wegman-Ostrosky T, Cruz-Robles D, Vidal Mill\u00e1n S. Familial erythrocytosis 2 and von Hippel-Lindau disease in the same pediatric patient. Bol Med Hosp Infant Mex. 2021, 78:341-345. 10.24875\/BMHIM.20000129","journal-title":"Bol Med Hosp Infant Mex"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.4103\/jcvjs.jcvjs_87_22","article-title":"Sporadic hemangioblastoma of cauda equina: a case report and brief literature review","volume":"13","author":"D' Oria S","year":"2022","unstructured":"D' Oria S, Giraldi D, Flores DA, Murrone D, D' Angelo V, Chaurasia B. Sporadic hemangioblastoma of cauda equina: a case report and brief literature review. J Craniovertebr Junction Spine. 2022, 13:265-270. 10.4103\/jcvjs.jcvjs_87_22","journal-title":"J Craniovertebr Junction Spine"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1776707","article-title":"En bloc resection for spinal cord hemangioblastomas: surgical technique and clinical outcomes","volume":"85","author":"Chen X","year":"2024","unstructured":"Chen X, Guo H, Zhang J, et al.. En bloc resection for spinal cord hemangioblastomas: surgical technique and clinical outcomes. J Neurol Surg A Cent Eur Neurosurg. 2024, 85:577-584. 10.1055\/s-0043-1776707","journal-title":"J Neurol Surg A Cent Eur Neurosurg"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30487-X","article-title":"Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial","volume":"19","author":"Jonasch E","year":"2018","unstructured":"Jonasch E, McCutcheon IE, Gombos DS, et al.. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2018, 19:1351-1359. 10.1016\/S1470-2045(18)30487-X","journal-title":"Lancet Oncol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00099-3","article-title":"Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study","volume":"26","author":"Srinivasan R","year":"2025","unstructured":"Srinivasan R, Iliopoulos O, Beckermann KE, et al.. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. 2025, 26:571-582. 10.1016\/S1470-2045(25)00099-3","journal-title":"Lancet Oncol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1054","article-title":"FDA approval summary: belzutifan for von Hippel-Lindau disease-associated tumors","volume":"28","author":"Fallah J","year":"2022","unstructured":"Fallah J, Brave MH, Weinstock C, et al.. FDA approval summary: belzutifan for von Hippel-Lindau disease-associated tumors. Clin Cancer Res. 2022, 28:4843-4848. 10.1158\/1078-0432.CCR-22-1054","journal-title":"Clin Cancer Res"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70075","article-title":"Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2\u03b1 dependent transcription","volume":"182","author":"Schweickert PG","year":"2025","unstructured":"Schweickert PG, Piovesan D, Mitchell CG, et al.. Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2\u03b1 dependent transcription. Br J Pharmacol. 2025, 182:4147-4167. 10.1111\/bph.70075","journal-title":"Br J Pharmacol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70239","article-title":"Targeting HIF-2\u03b1 in renal cell carcinoma: expanding upon belzutifan","volume":"132","author":"Rodriguez M","year":"2026","unstructured":"Rodriguez M, Qin Q, Tambar UK, Brugarolas J. Targeting HIF-2\u03b1 in renal cell carcinoma: expanding upon belzutifan. Cancer. 2026, 132:e70239. 10.1002\/cncr.70239","journal-title":"Cancer"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-026-01145-y","article-title":"The clinical landscape of HIF2\u03b1 inhibitors in oncology","volume":"23","author":"Saad E","year":"2026","unstructured":"Saad E, Machaalani M, McDermott DF, Choueiri TK. The clinical landscape of HIF2\u03b1 inhibitors in oncology. Nat Rev Clin Oncol. 2026, 23:501-519. 10.1038\/s41571-026-01145-y","journal-title":"Nat Rev Clin Oncol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/genes16010006","article-title":"Hypoxia-inducible factor in renal cell carcinoma: from molecular insights to targeted therapies","volume":"16","author":"Roviello G","year":"2024","unstructured":"Roviello G, De Gennaro I, Vascotto I, et al.. Hypoxia-inducible factor in renal cell carcinoma: from molecular insights to targeted therapies. Genes (Basel). 2024, 16:6. 10.3390\/genes16010006","journal-title":"Genes (Basel)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-inducible factor 2 alpha (HIF2\u03b1) inhibitors: targeting genetically driven tumor hypoxia","volume":"44","author":"Toledo RA","year":"2023","unstructured":"Toledo RA, Jimenez C, Armaiz-Pena G, Arenillas C, Capdevila J, Dahia PL. Hypoxia-inducible factor 2 alpha (HIF2\u03b1) inhibitors: targeting genetically driven tumor hypoxia. Endocr Rev. 2023, 44:312-322. 10.1210\/endrev\/bnac025","journal-title":"Endocr Rev"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13985-5","article-title":"Factors that predict progression of von Hippel-Lindau disease-related malignancy: a longitudinal cohort study","volume":"25","author":"Lee JH","year":"2025","unstructured":"Lee JH, Lee HY, Park JE, et al.. Factors that predict progression of von Hippel-Lindau disease-related malignancy: a longitudinal cohort study. BMC Cancer. 2025, 25:562. 10.1186\/s12885-025-13985-5","journal-title":"BMC Cancer"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2022.42.3.352","article-title":"Genetic counseling and long-term surveillance using a multidisciplinary approach in von Hippel-Lindau disease","volume":"42","author":"Yoon SJ","year":"2022","unstructured":"Yoon SJ, Kwon WK, Hong G, Jang JH, Jeong BC, Kim JH, Kim JW. Genetic counseling and long-term surveillance using a multidisciplinary approach in von Hippel-Lindau disease. Ann Lab Med. 2022, 42:352-357. 10.3343\/alm.2022.42.3.352","journal-title":"Ann Lab Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/447415-von-hippel-lindau-syndrome-an-updated-narrative-review-for-the-first-contact-clinician","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T20:43:43Z","timestamp":1784061823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/447415-von-hippel-lindau-syndrome-an-updated-narrative-review-for-the-first-contact-clinician"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":62,"URL":"https:\/\/doi.org\/10.7759\/cureus.112667","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}